ZILOSUL Drug Insight

“ZILOSUL Market Size, Forecast, and Emerging Insight – 2032” report offers an in-depth analysis of both market and emerging insights regarding ZILOSUL for the treatment of Knee osteoarthritis (OA), chronic pain, and osteoarthritis (OA) in the seven major markets. A detailed picture of the ZILOSUL for Knee osteoarthritis (OA), chronic pain, and osteoarthritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the ZILOSUL. The ZILOSUL market report provides insights into the ZILOSUL mechanism of action, dosage, and administration, as well as research and development, including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZILOSUL market forecast analysis in the 7MM, SWOT, analysts’ views, a comprehensive overview of market competitors, and a brief about other emerging therapies in Knee osteoarthritis (OA), chronic pain, and osteoarthritis.

ZILOSUL Drug Summary

Pentosan Polysulfate Sodium (PPS) is a semi-synthetic drug manufactured from European beech xylans that are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). These complex carbohydrates have a regulatory role in the body through interacting with proteins involved with inflammation. PPS also has a mild antithrombotic activity. Currently, the company is focusing on repurposing PPS (under the trademark ZILOSUL) for the treatment of Knee osteoarthritis and bone marrow lesions (BML), chronic heart failure (CHF), and alphaviral arthritis (Ross River Virus and Chikungunya), where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties. There are other disease applications involving inflammation that are of possible interest to the company.

In November 2021, Paradigm Biopharmaceuticals cleared a regulatory obstacle by receiving Investigational New Drug (IND) application approval from the US FDA for a Phase III clinical trial investigating its proprietary drug ZILOSUL – formulated from PPS for the treatment of pain associated with Knee osteoarthritis (OA), chronic pain, and osteoarthritis.

ZILOSUL® is a semi-synthetic drug developed by Paradigm Biopharmaceuticals Ltd, formulated from pentosan polysulfate sodium (PPS), which is derived from European beech tree wood chips. It mimics glycosaminoglycans (GAGs), exhibiting anti-inflammatory, tissue regenerative, and mild antithrombotic properties. Primarily targeted for osteoarthritis (OA) treatment, ZILOSUL® aims to alleviate pain and improve joint function. Paradigm has an exclusive supply agreement with bene pharmaChem, the only FDA-approved PPS manufacturer. In the U.S., annual ZILOSUL therapy costs are estimated between $2,000 and $3,000, potentially rising to $6,000 with disease-modifying indications. ZILOSUL® is currently undergoing Phase III clinical trials and has received FDA Fast Track

Scope of the ZILOSUL Market Report

The ZILOSUL market report provides insights into:

•  A comprehensive product overview including the ZILOSUL description, ZILOSUL mechanism of action, dosage and administration, research and development activities in Knee osteoarthritis (OA), chronic pain, and osteoarthritis.
•  Elaborated details on ZILOSUL regulatory milestones and other development activities have been provided in this report.
•  The ZILOSUL market report also highlights the ZILOSUL research and development activities in Knee osteoarthritis (OA), chronic pain, and osteoarthritis across the United States, Europe and Japan.
•  The ZILOSUL drugs market report also covers the patents information with expiry timeline around ZILOSUL.
•  The ZILOSUL drugs market report contains forecasted ZILOSUL sales for Knee osteoarthritis (OA), chronic pain, and osteoarthritis till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Knee osteoarthritis (OA), chronic pain, and osteoarthritis.
•  The ZILOSUL market report also features the SWOT analysis with analyst views for ZILOSUL in Knee osteoarthritis (OA), chronic pain, and osteoarthritis.

ZILOSUL Methodology

The ZILOSUL market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZILOSUL Analytical Perspective by DelveInsight

• In-depth ZILOSUL Market Assessment

This ZILOSUL market report provides a detailed market assessment of ZILOSUL for Knee osteoarthritis (OA), chronic pain, and osteoarthritis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the ZILOSUL market report provides forecasted ZILOSUL sales data from 2024 to 2032.

• ZILOSUL Clinical Assessment

The ZILOSUL market report provides the clinical trial information of ZILOSUL for Knee osteoarthritis (OA), chronic pain, and osteoarthritis, covering trial interventions, trial conditions, trial status, and start and completion dates.

ZILOSUL Market Report Highlights 

•  In the coming years, the market scenario for Knee osteoarthritis (OA), chronic pain, and osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the ZILOSUL market.  
•  The ZILOSUL companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZILOSUL dominance.
•  Other emerging products for Knee osteoarthritis (OA), chronic pain, and osteoarthritis are expected to give tough market competition to ZILOSUL, and the launch of late-stage emerging therapies in the near future will significantly impact the ZILOSUL market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZILOSUL in Knee osteoarthritis (OA), chronic pain, and osteoarthritis.
•  Our in-depth analysis of the forecasted ZILOSUL sales data from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZILOSUL in Knee osteoarthritis (OA), chronic pain, and osteoarthritis.

Key Questions

•  What is the product type, route of administration, and mechanism of action for ZILOSUL?
•  What is the ZILOSUL clinical trial status of the study in Knee osteoarthritis (OA), chronic pain, and osteoarthritis, and what is the study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the ZILOSUL drug development?
•  What are the key designations that have been granted to ZILOSUL for Knee osteoarthritis (OA), chronic pain, and osteoarthritis?
•  What is the forecasted market scenario of ZILOSUL for Knee osteoarthritis (OA), chronic pain, and osteoarthritis?
•  What are the forecasted ZILOSUL sales in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available, and how are these competing with ZILOSUL for knee osteoarthritis (OA), chronic pain, and osteoarthritis?
•  Which are the late-stage emerging therapies under development for treating Knee osteoarthritis (OA), chronic pain, and osteoarthritis?